PolyTherics extends ThioBridge antibody drug conjugate collaboration with ... News-Medical.net MacroGenics has two antibody technology platforms, a Dual-Affinity Re-Targeting (DART™) bi-specific platform, in which a single recombinant molecule is able to target two different antigens, and Fc-optimized antibodies with improved effector function. |
